At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
about
Haploidentical Transplantation in Children with Acute Leukemia: The Unresolved IssuesT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectThe role of gamma delta T cells in haematopoietic stem cell transplantationTIM-3/Gal-9 interaction induces IFNγ-dependent IDO1 expression in acute myeloid leukemia blast cells.γδ T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-αβ+/CD19+ lymphocytesIn vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells.Haematological malignancies: at the forefront of immunotherapeutic innovation.The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB.BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemiaAt the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor.Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections.Stem cell transplants for myelodysplastic syndromes: refining the outcome predictions.Mobilization of healthy donors with plerixafor affects the cellular composition of T-cell receptor (TCR)-αβ/CD19-depleted haploidentical stem cell grafts.High-Risk Leukemia: Past, Present, and Future Role of NK Cells.
P2860
Q26750671-E1D0294C-C060-4AAF-81F6-6922D57F76EDQ26826830-7767FDC1-BCBE-4F75-B5EA-E758FD29B16DQ27030355-FB8DADA6-15C6-4EEE-A95B-8C9D693891DAQ35505155-77A28266-D36D-49B9-A341-7BA497ECD66CQ35634919-79F084EB-5B50-475A-BF6A-4B60967CFDE2Q35803534-75A5FC69-54E7-401D-A648-93150940BC5CQ35880618-B86C9D65-1D2E-4910-91DF-7C5143A4E0B7Q36723387-E6DA6B13-BE9B-485A-958A-D70DAD141955Q37380386-13F8A13D-2610-4A12-9756-56E58AC15355Q38151057-25523DA4-6C03-49F3-984C-B3D571B8015FQ38569646-C1FE286A-22A4-44E8-A3BB-B927CB858975Q38875042-3B5C20ED-887C-487A-9EC5-1391FA308374Q41678768-3D955E3D-4648-43CA-8549-7E586E86112FQ42732201-32ED0BCA-4BCD-4472-B196-7BDE648AA757Q42869339-ED3E5CB5-A1EA-491A-8A3F-3AACD49C40DEQ55172823-7DC206DC-1223-41C5-ABCB-C2BEA7BA6881
P2860
At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
@en
type
label
At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
@en
prefLabel
At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
@en
P2860
P50
P356
P1476
At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
@en
P2860
P304
P356
10.1189/JLB.0613343
P577
2013-10-04T00:00:00Z